SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: quidditch who wrote (56)12/11/2001 8:41:53 PM
From: IRWIN JAMES FRANKEL  Read Replies (1) of 118
 
Hi quid,

I hope someone else can help with your question.

I do not understand the MOA for Zetia. But to the extent that it lowers LDL's - my bet is that it will not be able to match the benefits of Niaspan/Advicor because they act directly on HDL's to raise them. Further, N/A lowers triglicerides and lipo-protein a (small a). These are therapeutically important results that would not be obtained by just lowering LDL's.

I don't see BMY involved. That is supported by management comments in the CC.

KOSP needs a good partner.

ij
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News